Although a few studies have utilized miRNAs, EV concentrations, and cancer antigens to monitor and predict response to treatments [38–40], our study is a novel attempt to use tumor-derived EVs to assess ABC transporters isolated from the plasma of patients with breast cancer who are treated with NAC. The gene discussed is ABCG2; the disease is neoplasm.